NASDAQ: CYRX · Life Sciences · 4 alerts · CIK 1124524
Share price
$19.80Close, Nov 16
Market cap
$1B
Shares outstanding
50.7MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cryoport, Inc. filings on SEC EDGAR ↗
Mark W. Sawicki, CSO, sold 10,000 shares of Cryoport, Inc. at $19.93 a share, worth $199K in total on Nov 10, 2026. Shares held after the trade: 92,356 (-9.8%).
Cryoport Insider Daniel M. Hancock Sells $1.5M of Stock
Daniel M. Hancock sold 74,379 shares of Cryoport, Inc. at $20.21 a share, worth $1.5M in total on Nov 9, 2026. Shares held after the trade: 69,052 (-51.9%).
Cryoport reported total revenue of $50.2 million for Q3 2026, a 13.5% increase compared to the same period in 2025. The company experienced a net loss of $10.9 million for the quarter, driven by increased operating costs and a $4.4 million other expense item, while maintaining a strong cash and short-term investment position of $393.1 million.
Cryoport reported Q3 2026 revenue of $50.2 million, a 14% increase year-over-year, driven by 20% growth in commercial Cell and Gene Therapy revenue. The company achieved positive adjusted EBITDA of $1.1 million and raised its full-year 2026 revenue guidance to a range of $197 million to $199 million.
Term
Q3 2026
“Cryoport delivered third quarter revenue of $50.2 million, reflecting continued momentum across our core cell and gene therapy (CGT) business. Revenue from commercial CGT clients increased 20% year over year, BioStorage/BioServices revenue expanded 25%, and total Life Sciences Services revenue grew 18%, underscoring the strength of our integrated platform and the growing demand for our solutions.”
Jerrell Shelton, CEO of Cryoport
“Our strong year-to-date performance, combined with expanding support of commercial therapies, deepening customer relationships, a robust clinical trial pipeline, and continued demand for MVE’s industry-leading products, gives us confidence in our outlook. As a result, we are increasing our full-year 2026 revenue guidance to a range of $197 million to $199 million.”